Nossa Ciência

Publicações em artigos científicos

Col, V.D. et al. (2016)

Effects of NADH and NADH + NMN Co-Formulation on Human Dermal Fibroblasts: Preliminary In Vitro Analysis

BioMed 2026, 6(4), 23; DOI: https://doi.org/10.3390/biomed6040023

da Costa VR et al. (2026)

Donor-dependent immunomodulatory effects of human dental pulp stem cells on macrophages

Front. Immunol. 17:1798470; DOI: https://doi.org/10.3390/brainsci15080865

D’Amélio et al. (2026)

Transcriptomic Dissection of Bothrops moojeni Venom Reveals Fraction-Specific Modulation of Host Cellular Pathways

Int. J. Mol. Sci. 2026, 27(13), 5943; DOI: https://doi.org/10.3390/ijms27135943

Col, V.D.; Ribas, F.F.; Araldi, R.P. (2026)

Regenerative Approaches to Enhance the Skin Microenvironment and Boost Aesthetic Efficacy: A Narrative Review

Int. J. Mol. Sci. 2026, 27(11), 4716; DOI: https://doi.org/10.3390/ijms27114716

Dal Col, Ribas and Araldi. (2026)

Rejuvenation by Design: Building Cosmetic Products with Extracellular Vesicle Technology, the Example of Exo. Reset®

Handbook of Extracellular Vesicles – Biology, Production, and the Regulatory Road to Market; DOI: 10.5772/intechopen.1015350

Duarte et al. (2026)

Parkinson’s Disease: From Metabolism to Genetics—A Comprehensive Review

Curr. Issues Mol. Biol. 2026, 48(3), 254; DOI: 10.3390/cimb48030254

Araldi et al. (2025)

Mechanism of Action of NestaCell®: A Bioinformatics-Guided Translational Approach for Therapeutic Modulation in Huntington’s Disease

In Mesenchymal Stem Cell – Biology, Therapeutics, and Beyond, Ed. IntechOpen, London, 2025; DOI: 10.5772/intechopen.1012979

D’Amélio et al. (2025)

Impact of substrate choice on human osteoclast differentiation and secretome: Implications for targeted therapeutic development

PLoS One 20(10): e0333180; DOI: https://doi.org/10.1371/journal. pone.0333180

Dal Col et al. (2025)

The Transformative Impact of Extracellular Vesicles on the Cosmetics Industry: A Comprehensive Review

Cosmetics 2025, 12(5), 191; https://doi.org/10.3390/cosmetics12050191

Araldi et al. (2025)

AI-Enhanced Transcriptomic Discovery of Druggable Targets and Repurposed Therapies for Huntington’s Disease

Brain Sci. 2025, 15(8), 865, https://doi.org/10.3390/brainsci15080865

Dias-Pinto et al. (2025).

From Brain to Blood: Uncovering Potential Therapeutical Targets and Biomarkers for Huntington’s Disease Using an Integrative RNA-Seq Analytical Platform (BDASeq®)

Cells 2025, 14(13), 976; https://doi.org/10.3390/cells14130976

D’Amélio et al. (2025)

Comprehensive RNA-Seq Analysis of Human Osteoclast Function in Response to Bothrops moojeni Venom Fractions: Pathways of Bone Resorption and Cytoskeletal Disruption

Comprehensive RNASeq Analysis of Human Osteoclast Function in Response to Bothrops moojeni Venom Fractions: Pathways of Bone Resorption and Cytoskeletal Disruption. Toxins 2025, 17, 358; DOI: https://doi.org/10.3390/ toxins17070358

Alievi et al. (2025)

Preclinical In vitro evaluation of extracellular vesicles from human dental pulp stem cells for the safe and selective modulation of anaplastic thyroid carcinoma

Int. J. Mol. Sci. 2025, 26(13), 6443; DOI: 10.3390/ijms26136443

Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.

Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.

Dias-Pinto et al. (2024).

How does the age of control individuals hinder the identification of target genes for Huntington’s disease?

Front Genet. 20:15: 1377237. DOI: 10.3389/fgene.2024.1377237.

Prêmios Internacionais

Araldi et al. (2024).

Novel pharmaceutical targets and prognostic biomarkers for Huntington’s disease: New perspectives for the drug development. Proceedings from MENA Congress for Rare Disease

16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.

Dias-Pinto et al. (2024).

BDASeq: A novel and powerful tool able to accurately discover therapeutic targets for the treatment of rare diseases.

Proceedings from MENA Congress for Rare Disease, 16-19 May, Abu Dhabi, UAE. Ther Adv Rare Dis. 5: 1-33. DOI: 10.1177/26330040241238936.